<a href="https://laohu8.com/S/PMHS">Polomar Health</a> Services Inc. Enters Amended Agreement with ForHumanity for Exclusive Marketing of Inhalable Medications
Polomar Health Services Inc., a Nevada-based corporation, has announced the execution of an Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity, Inc., and Island Group 40, LLC. Effective August 19, 2025, this agreement grants ForHumanity exclusive marketing rights for Polomar's inhalable sildenafil and inhalable eletriptan products until March 31, 2026. The exclusivity can be extended based on revenue milestones, with potential extensions through December 31, 2026. Polomar Specialty Pharmacy, a wholly owned subsidiary, will handle prescription fulfillment, while IG4 will provide account management services. The agreement is set for an initial term ending September 16, 2028, with possible renewals contingent on achieving specific revenue targets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polomar Health Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-025989), on August 29, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。